Vaccine effectiveness was 8 % ( 95 % CI 1-14 ) and the incidence rate difference 0.12 per person-year corresponding to the number needed to vaccinate of five ( 95 % CI 3-67 ) to prevent one purchase during the 2 year follow-up for combined PHiD-CV10 three plus one and two plus one infant schedules .